Abstract:ObjectiveTo evaluate whether the intense simplified strategy, which comprises short term intensive insulin therapy (SIIT) followed by subsequent oral antihyperglycaemic regimens, could improve long term glycaemic outcomes in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia.DesignMulticentre, open label, randomised trial.Setting15 hospitals in China between December 2017 and December 2020.Participants412 patients with newly diagnosed type 2 diabetes and significant hyperglycaemia (HbA1c ≥8.5%).InterventionsAll randomised participants initially received SIIT for 2-3 weeks, followed by linagliptin 5 mg/day, metformin 1000 mg/day, combination linagliptin plus metformin, or lifestyle modification alone (control) for 48 weeks.Main outcome measuresThe primary outcome was the percentage of participants achieving HbA1c <7.0% at week 48 after SIIT. Secondary outcomes included glycaemic control, β cell function, and variations in insulin sensitivity.Results412 participants were randomised. At baseline, the mean age was 46.8 (standard deviation 11.2) years, mean body mass index was 25.8 (2.9), and mean HbA1c was 11.0% (1.9%). At week 48, 80% (78/97), 72% (63/88), and 73% (69/95) of patients in the linagliptin plus metformin, linagliptin, and metformin groups, respectively, achieved HbA1c <7.0%, compared with 60% (56/93) in the control group (P=0.02 overall; P=0.003 for linagliptin plus metformin versus control; P=0.12 for linagliptin versus control; P=0.09 for metformin versus control). Additionally, 70% (68/97), 68% (60/88), and 68% (65/95) of patients in the linagliptin plus metformin, linagliptin, and metformin group, respectively, achieved HbA1c <6.5% compared with 48% (45/93) in the control group (P=0.005 overall; P=0.005 for linagliptin plus metformin versus control; P=0.01 for linagliptin versus control; P=0.008 for metformin versus control; all were significant after adjustment for multiple comparisons). Thus, compared with the control group, participants in the linagliptin plus metformin group were more likely to achieve HbA1c <7.0% at week 48 (odds ratio 2.78, 95% confidence interval 1.37 to 5.65; P=0.005). Moreover, the linagliptin plus metformin group showed the most significant improvement in fasting plasma glucose and β cell function indices. All treatments were well tolerated.ConclusionsThe intense simplified strategy using subsequent oral therapies post-SIIT, especially the linagliptin plus metformin combination, sustainably improved glycaemic control and β cell function in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia. This approach offers a promising direction for decision making in the clinical management of type 2 diabetes mellitus.Trial registrationClinicalTrials.gov NCT03194945

2320-PUB: Effects of Sequential Therapy Using Metformin plus Pioglitazone following Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed T2DM

1032-P: Time-in-Range during Short-Term Intensive Insulin Therapy Is Associated with Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes

[The Effects of Early Intensive Therapy on Islet Beta Cell Function and Long-Term Glycemia Control in Newly Diagnosed Type 2 Diabetic Patients with Different Fasting Plasma Glucose Levels.].

Effect of Initial Intensive Insulin Therapy Followed by Sitagliptin on ? Cell Function in Patients with New Onset Type 2 Diabetes

Efficacy and Tolerability of Sitagliptin and Metformin Compared with Insulin As an Initial Therapy for Newly Diagnosed Diabetic Patients with Severe Hyperglycaemia

Management of Patients Using Combination Therapy with Pioglitazone and a Dipeptidyl Peptidase-4 Inhibitor: an Analysis of Initial Versus Sequential Combination Therapy

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial

The Beneficial Effect Of Metformin On Beta-Cell Function In Non-Obese Chinese Subjects With Newly Diagnosed Type 2 Diabetes

Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial

Comparison of the effect of different short-term intensive anti-diabetic therapies on newly diagnosed type 2 diabetic patients.

Safety And Efficacy Of Sitagliptin In Combination With Transient Continuous Subcutaneous Insulin Infusion (Csii) Therapy In Patients With Newly Diagnosed Type 2 Diabetes

Efficacy and Safety of Metformin and Sitagliptin Based Triple Antihyperglycemic Therapy (STRATEGY): a Multicenter, Randomized, Controlled, Non-Inferiority Clinical Trial.

Effects of Sitagliptin As Initial Therapy in Newly Diagnosed Elderly Type 2 Diabetics: A Randomized Controlled Study

Decreased circulating dipeptidyl peptidase-4 activity after short-term intensive insulin therapy predicts clinical outcomes in patients with newly diagnosed type 2 diabetes

1373-P: Changes in Body Composition Are Associated with Improvement of ß-Cell Function and Insulin Sensitivity after Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed Type 2 Diabetes

Remission of Hyperglycemia Following Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetic Patients: a Long-Term Follow-Up Study.

DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY

Intensive Insulin Therapy Combined With Metformin Is Associated With Reduction In Both Glucose Variability And Nocturnal Hypoglycaemia In Patients With Type 2 Diabetes